AngioDynamics, Inc.

AngioDynamics, Inc. (ANGO) Stock Analysis

$16.130

+0.286 (+1.77%)At close

Loading chart…
High
16.220
Open
15.800
VWAP
15.99
Vol
358.53K
Mkt Cap
237.52M
Low
15.630
Amount
5.73M
EV/EBITDA, TTM
-2,978.47

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

AI analysis of AngioDynamics, Inc. (ANGO)

buy

AngioDynamics Inc is a good buy right now due to its recent strong performance and positive catalysts. The current price is $15.85, and the company reported a 25% year-to-date change, alongside a significant 8% revenue growth in Q4 2026. The RSI is at 57.545, indicating a healthy momentum. However, the main risk is the forward P/E ratio of 96.15, suggesting that the stock may be overvalued based on future earnings expectations.

Analyst Ratings (5)

+19.84% upside
Hold
1 Buy
4 Hold
0 Sell
Current: 16.13
Low
16.00
Average
19.33
High
24.00

Canaccord

2026-07-15

Price Target

$20

Buy

H.C. Wainwright

2026-07-15

Price Target

$19

Buy

Freedom Broker

2026-04-06

Price Target

$16

Buy

Canaccord

2026-04-06

Price Target

$16

Buy

Canaccord

2025-07-16

Price Target

$17

Buy

Valuation Metrics

The current forward P/E ratio for AngioDynamics, Inc. (ANGO) is 96.15, compared to its 5-year average forward P/E of -69.22.

Forward P/E

Fair
5Y Average P/E
-69.22
Current P/E
96.15
Overvalued
231.14
Undervalued
-369.58

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-93.02
Current EV/EBITDA
-2978.47
Overvalued
387.52
Undervalued
-573.56

Forward P/S

Fair
5Y Average P/S
1.58
Current P/S
1.84
Overvalued
2.28
Undervalued
0.87

Alphio AI Price Scenarios for ANGO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ANGO

$10.16

Scenario price

B

Base

Base · 50%ANGO

$9.75

Scenario price

B

Bear

Bear · 25%ANGO

$9.26

Scenario price

Whales holding ANGO

A

Armistice Capital LLC

+ HoldingANGO

+16.64%

3M Return

Events Timeline

2026-06-17 (ET)

09:30:00

AngioDynamics Receives FDA Approval to Initiate RELIEF Study

2026-05-13 (ET)

09:10:00

AngioDynamics Announces Two-Year Results for NanoKnife System

2026-04-02 (ET)

16:40:00

Major U.S. Averages Mixed as Oil Prices Rise to $111.54

12:30:00

Major Averages Decline as Oil Prices Rise

06:10:00

Company Reports Q3 Revenue of $78.4M, Beating Expectations

News

ANGO FAQ — answered by Alphio AI

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics Inc is a good buy right now due to its recent strong performance and positive catalysts. The current price is $15.85, and the company reported a 25% year-to-date change, alongside a significant 8% revenue growth in Q4 2026. The RSI is at 57.545, indicating a healthy momentum. However, the main risk is the forward P/E ratio of 96.15, suggesting that the stock may be overvalued based on future earnings expectations.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started